Anna jaques hospital
Beth israel deaconess medical center
Brigham and womens hospital
Cape cod hospital
Caritas holy family hospital and medical center
Caritas norwood hospital
Good samaritan medical center
Lawrence general hospital
Lowell general hospital
Massachusetts general hospital
Milford regional medical center
Umass memorial medical center
Brigham & Women's Hospital
Dana Farber Cancer Institute
Young women diagnosed with early-stage ovarian cancer or borderline malignancy of the ovary: a focus on fertility and sexual function.
J Psychosoc Oncol., 30(4):387-401 (2012)
End of life issues in older patients.
Semin. Oncol., Apr;31(2):274-81 (2004)
Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer.
J Pain Symptom Manage., Dec;30(6):563-9 (2005)
Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
J. Clin. Oncol., Dec;26(35):5761-6 (2008)
Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed MÃ¼llerian tumors.
Gynecol. Oncol., Feb;112(2):394-9 (2009)
Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma.
Gynecol. Oncol., Dec;115(3):401-6 (2009)
Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.
J. Clin. Oncol., Nov;27(33):5601-6 (2009)
Influence of patients' preferences and treatment site on cancer patients' end-of-life care.
Cancer., Oct;116(19):4656-63 (2010)
Place of death: correlations with quality of life of patients with cancer and predictors of bereaved caregivers' mental health.
J. Clin. Oncol., Oct;28(29):4457-64 (2010)
Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer.
Gynecol. Oncol., Jul;126(1):41-6 (2012)
A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer.
Gynecol. Oncol., Dec;95(3):624-31 (2004)
A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial.
Gynecol. Oncol., Oct;99(1):50-7 (2005)
Bevacizumab and its use in epithelial ovarian cancer.
Future Oncol., Mar;7(3):365-79 (2011)
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy.
Science., Nov;334(6059):1129-33 (2011)
Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
Gynecol. Oncol., Oct;127(1):63-9 (2012)
Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent MÃ¼llerian tumors.
Gynecol. Oncol., Sep;90(3):610-8 (2003)
Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy.
Gynecol. Oncol., May;125(2):362-6 (2012)
Co-Author, "Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer"
Journal of Clinical Oncology
Co-Author, "Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer"
Clinical Cancer Research
Co-Author, "Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases"
The Journal of Allergy and Clinical Immunology